Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.32 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.32 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | CDC25A | P30304 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7070555 | 0.85 | GRIN1 (0.35) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7067258 | 0.84 | ALDH1A1 (0.35) | POLBALDH1A1TSHRLMNAPKM | |
| SCHEMBL7070306 | 0.77 | POLB (0.33) | HPGDPOLBCXCL8NOD2NOD1 | |
| SCHEMBL2471003 | 0.77 | GRIN1 (0.42) | ALDH1A1TSHRHSD17B10MEN1KMT2A | |
| SCHEMBL2471363 | 0.75 | GRIN1 (0.39) | POLBALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8760732 | 0.75 | UPP1 (0.46) | HPGDPOLBALDH1A1TSHRMAPK1 | |
| SCHEMBL2471911 | 0.75 | GRIN1 (0.39) | POLBALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7068424 | 0.75 | TDP1 (0.33) | HPGDPOLBCXCL8NOD2NOD1 | |
| SCHEMBL2469750 | 0.74 | GRIN1 (0.38) | POLBALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL7072203 | 0.74 | PKM (0.30) | PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1986651-B1 | USE OF A PYRIMIDINEDIONE DERIVATIVE FOR PREVENTING OR TREATING HEPATITIS C | SAMJIN PHARM CO LTD (KR) | 2011-10-05 | — | — | EP | claimed |
| US-7851479-B2 | Use of pyrimidinedione derivative for preventing or treating hepatitis C | SAMJIN PHARM. CO., LTD. (KR) | 2010-12-14 | — | — | US | claimed |
| US-20090023764-A1 | Use of Pyrimidinedione Derivative for Preventing or Treating Hepatitis C | SAMJIN PHARM. CO., LTD. (KR) | 2009-01-22 | — | — | US | claimed |
| US-7851479-B2 | Use of pyrimidinedione derivative for preventing or treating hepatitis C | SAMJIN PHARM. CO., LTD. (KR) | 2010-12-14 | — | — | US | disclosed |
| US-7851479-B2 | Use of pyrimidinedione derivative for preventing or treating hepatitis C | SAMJIN PHARM. CO., LTD. (KR) | 2010-12-14 | — | — | US | disclosed |
| US-20090023764-A1 | Use of Pyrimidinedione Derivative for Preventing or Treating Hepatitis C | SAMJIN PHARM. CO., LTD. (KR) | 2009-01-22 | — | — | US | disclosed |
| US-20090023764-A1 | Use of Pyrimidinedione Derivative for Preventing or Treating Hepatitis C | SAMJIN PHARM. CO., LTD. (KR) | 2009-01-22 | — | — | US | disclosed |
| US-5922727-A | 1-((SUBSTITUTED)CYCLOALK(EN)YLALKYL)-6-((SUB)PHENYL(CARBONYL, SULFIDE, OR OXO))-2,4-PYRIMIDINEDIONE DERIVATIVES HAVING SUPERIOR ANTIVIRAL ACTIVITIES; HIV | SAMJIN PHARMACEUTICAL CO., LTD (KR) | 1999-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023764-A1 | Use of Pyrimidinedione Derivative for Preventing or Treating Hepatitis C | DPYD, UMPS, TYMP | HPGD 161/4885POLB 264/4885DAO 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.